Senex Biotechnology is a drug discovery and development company focused on oncology therapeutics. Senex was founded by Dr. Igor Roninson, based on the discovery in his academic laboratory of a novel biological pathway involved in cancer and other aging-associated diseases. Senex has discovered small molecules that inhibit this pathway, identified their pertinent molecular targets, and developed selective inhibitors of these novel targets. Function based genomic screening enabled the identification of additional new targets that are required by tumor cells but not by normal tissues. Leads against three of Senex’s targets are under development; the most advanced lead is anticipated to enter clinical trials within a year.